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Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become the
cornerstone in the treatment of lung cancers that harbor EGFR mutations, but also play an
important role in the treatment of other lung cancers and have been investigated among
various types of solid tumors. However, these drugs have been associated with an increase
in the risk of potentially life-threatening adverse event, such as arterial and venous thrombotic
events. We performed a meta-analysis to determine the incidence and risk of fatal adverse
events (FAEs) in cancer patients treated with EGFR-TKIs. Incidence rates, relative risks
(RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total
of 13,825 patients from 22 trials were included. Among patients treated with EGFR-TKIs, the
overall incidence of FAEs was 1.9% (95%CI: 1.2e2.9%), and the risk of FAEs was 0.99 (95%CI:
0.70e1.41, p Z 0.97). No increase in FAEs was detected in any prespecified subgroup. Addi-
tionally, using EGFR-TKIs as salvage treatment significantly reduced the risk of FAEs when
compared to the controls (RR 0.51, 95%CI: 0.29e0.87, p Z 0.013). In conclusion, this analysis
suggests that the use of EGFR-TKIs does not increase the risk of FAEs in patients with advanced
solid tumors, and EGFR-TKIs are safety and tolerable for cancer patients, especially for those
previously treated patients.
ª 2013 Elsevier Ltd. All rights reserved.21 64369181 58430; fax: þ86 021 64701361.
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Treatment-related mortality with EGFR-TKIs 1281The increased understanding of tumor biology and the
availability of drugs targeting key biological mechanisms
required for tumor growth provide novel approaches for the
treatment of cancer. One such therapeutic target is the
epidermal growth factor receptor (EGFR) pathway, a crit-
ical mediator of tumor proliferation and angiogenesis [1,2].
Indeed, two small molecular agents that target the tyrosine
kinase domain of the EGFR, erlotinib and gefitinib, are
approved in many countries for the treatment of locally
advanced or metastatic non-small-cell lung cancer (NSCLC)
as second- or third-line therapy [3e5]. And second-
generation tyrosine kinase inhibitors, such as neratinib
and afatinib, have undergone evaluation among different
epithelial cancers [6e10]. In contrast with traditional
chemotherapy agents, EGFR-TKIs present a favorable
toxicity profile with the most frequently adverse events
(AEs) being rash, diarrhea, and nausea [11e13]. However,
these small-molecule TKIs have also been associated with a
new set of adverse events, some of which may be poten-
tially life threatening, such as arterial thrombosis and
venous thrombosis [14e16]. Indeed, fatal adverse events
(FAEs) have occasionally been reported in several clinical
trials with EGFR-TKIs, although no significant and definitive
data have been established. We thus conducted this meta-
analysis to determine the incidence and risk of FAEs asso-
ciated with the clinical use of EGFR-TKIs.
Trials were selected from those published in PubMed
between January 1, 1990, and December 31, 2012, with
“erlotinib”, “gefitinib”, “Iressa”, “Tarceva”, “randomized
controlled trial (RCT)”, and “cancer” as key words. Inclu-
sion criteria included (1) prospective phase III RCTs evalu-
ating EGFR-TKIs (erlotinib and gefitinib) in patients with
cancer, (2) assigned participants to EGFR-TKIs or non-EGFR-
TKIs-containing therapy, and (3) available data on FAEs.
The quality of reports of clinical trials was assessed and
calculated using the 5-item Jadad scale as previously
described [17]. Data abstraction was conducted indepen-
dently by two investigators (Q.W.X. and S.Z.), and any
discrepancy between the reviewers was resolved by
consensus. The primary end point of the analysis wasFigure 1 Relative risk of fatal adverse events associatreatment emergent, non-disease-related, fatal adverse
events. Adverse events were defined as per versions two or
three of the National Cancer Institute’s Common Termi-
nology Criteria for Adverse Events (CTCAE) criteria [18].
Both versions are similar in defining fatal adverse events as
grade five, though version three requires attribution to
specific adverse events while version two did not have such
requirements. We excluded events that were reported as
related to disease progression, but included all events with
unspecified attribution and included events regardless of
attribution to treatment provided that they were not
related to disease progression.
Analyses were performed by using Stata version 12.0
software and Open Meta-Analyst software version 4.16.12
(Tufts University, URL http://tuftscaes.org/open_meta/).
For one study that reported zero events in the arms, we
applied the classic half-integer correction to calculate the
RR and variance [19]. Random effects models were used
regardless of the actual inter-study heterogeneities, which
were quantified using the c2-based Q statistic [20]. Indi-
vidual trials were pooled and weighted by the DerSimo-
nianeLaird method. The incidence and relative risk of FAEs
were calculated for each study along with appropriate 95%
confidence intervals (CIs) and p values. A two-side p less
than 0.05 was considered to indicate statistical signifi-
cance. We also conducted the following prespecified sub-
group analyses: different tumor types, EGFR-TKIs,
countries, EGFR-TKIs-based regimens, controlled therapy,
and treatment strategy.
Of the 650publications identifiedduring the initial search,
22 trials met criteria for inclusion (Supplementary Fig. 1,
available online). The median Jadad score was 3
(rangeZ 3e5). No evidence of publication bias was detected
byBegg test (pZ0.77). A total of 13,825patients (EGFR-TKIs,
n Z 7508; non-EGFR-TKIs, n Z 6317) were included in the
analysis (Supplementary Table 1, available online).
In the EGFR-TKIs group, 231 patients experienced FAEs
compared with 198 patients in non-EGFR-TKIs group. The
summary incidence of FAEs in patients receiving EGFR-TKIs
was 1.9 (95%CI: 1.2e2.9%) (Supplementary Fig. 2, availableted with EGFR-TKIs versus non-EGFR-TKIs therapy.
Table 1 Incidence and relative risk of FAEs with EGFR-TKIs according to prespecified subgroups.
Groups Studies, n Fatal adverse events,
n/total, n
Incidence of fatal adverse
events, % (95%CI)
RR (95%CI) p Value
EGFR-TKIs Control EGFR-TKIs Control
Tumor type
NSCLC 19 224/6771 194/5743 2.1 (1.3e3.3) 2.1 (1.3e3.4) 1.00 (0.72e1.40) 0.98
Pancreatic cancer 1 6/282 0/280 2.1 (1.0e4.7) 0.2 (0e2.8) 12.91 (0.73e228.05) 0.08
Head and neck cancer 1 1/324 4/159 0.3 (0e2.2) 2.5 (0.9e6.5) 0.12 (0.01e1.09) 0.06
Biliary-tract cancer 1 0/135 0/131 0 0 e e
EGFR-TKIs
Erlotinib 10 105/4373 62/3248 1.7 (1.0e2.9) 1.9 (1.2e2.9) 1.13 (0.72e1.78) 0.60
Gefitinib 12 126/3135 136/3069 2.2 (1.1e4.3) 2.5 (1.3e4.9) 0.87 (0.50e1.51) 0.61
Country
Asia 10 38/1724 19/1678 2.2 (1.4e3.5) 1.2 (0.6e2.4) 1.65 (0.98e2.78) 0.058
Non-Asia 12 193/5784 179/4639 1.9 (1.1e3.5) 2.6 (1.5e4.5) 0.80 (0.51e1.25) 0.32
EGFR-TKIs-based regimens
Monotherapy 17 124/5306 113/4448 1.7 (1.1e2.7) 2.2 (1.5e3.3) 0.83 (0.54e1.29) 0.41
Combinations 5 107/2202 85/1869 2.9 (1.1e7.1) 1.6 (0.4e6.2) 1.48(0.75e2.92) 0.26
Treatment strategy
First-line 12 191/4462 126/3526 2.7 (1.6e4.4) 1.8 (0.9e3.6) 1.22 (0.98e1.52) 0.08
Salvage treatment 8 37/2744 70/2334 1.4 (0.7e2.7) 2.6 (1.4e4.7) 0.51 (0.29e0.87) 0.013
Maintenance 2 3/302 2/457 1.3 (0.3e6.0) 0.6 (0.2e1.9) 1.71 (0.10e28.59) 0.71
Controlled therapy
Placebo 3 60/1758 23/952 1.7 (0.4e7.2) 1.1 (0.2e7.0) 1.29 (0.81e2.07) 0.29
Active therapy 19 171/5750 175/5365 1.8 (1.1e3.0) 1.9 (1.2e3.3) 0.94 (0.63e1.41) 0.76
Overall 22 231/7508 198/6317 1.9 (1.2e2.9) 1.9 (1.2e3.0) 0.99 (0.70e1.41) 0.97
Abbreviations: NSCLC, non-small-cell lung cancer; EGFR-TKIs, epidermal growth factor receptor tyrosine kinase.
1282 W.-X. Qi et al.online). The relative risk of FAE for EGFR-TKIs versus non-
EGFR-TKIs therapy was 0.99 (95%CI: 0.70e1.41; p Z 0.97)
(Fig. 1). To better determine possible relationships be-
tween EGFR-TKIs and FAEs, we performed several explor-
atory subgroup analyses (Table 1). No statistically
significant increase in the relative risk of FAEs with EGFR-
TKIs was observed according to tumor types, EGFR-TKIs,
countries, EGFR-TKIs-based regimens, controlled therapy,
and treatment strategy. Additionally, using EGFR-TKIs as
salvage treatment significantly reduced the risk of FAEs
when compared to the controls (RR 0.51, 95%CI: 0.29e0.87,
p Z 0.013). Our analysis revealed a very low event rate of
FAEs (1.9%) with EGFR-TKIs, Strict eligibility criteria in
phase III randomized controlled trials may have contrib-
uted, at least in part, to the lower incidence of FAEs
observed. Notably, this should have impacted both EGFR-
TKIs and non-EGFR-TKIs arms equally.
Our meta-analysis was not based on individual patient
data, and meta-analyses based on published data tended to
overestimate treatment effects compared with individual
patient data analyses. In addition, it precluded a more
comprehensive analysis such as adjusting for baseline fac-
tors and other differences that existed between the trials
from which the data were pooled. Therefore, the results
must be interpreted cautiously, as an individual patient
data-based meta-analysis would give more reliable esti-
mation than one based on abstracted data. Another limi-
tation was that trials reported zero FAEs in one or both arms
were also included for analysis. In this setting, using
random effects models and continuity corrections wouldbias the results toward null. But we felt that including trials
reporting zero FAEs would provide the most conservative
estimate. Additionally, different treatment strategy,
duration, and regimens contributed to increase the clinical
heterogeneity of the meta-analysis, which made the
interpretation of the meta-analysis more problematic,
although we performed subgroup analysis and combined
the individual trial using a random effect model.
In conclusion, the present study reveals that FAEs in
patients treated with EGFR-TKIs are uncommon. We do not
detect an increase in the relative risk of FAEs with EGFR-
TKIs therapy compared with non-EGFR-TKIs therapy, and
EGFR-TKIs are safety and tolerable for cancer patients,
especially for those previously treated patients.
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